Clinical trials: CTEPH
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy
Severe CTEPH leads to an impaired physical capacity and a restricted quality of life and poor prognosis. Pulmonary endarterectomy represents the best choice as therapy, when the thrombi are located in the central pulmonary…
- Trial name
- NCT00477724
- Testing
- exercise and respiratory therapy, sedentary control group
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Venous Thromboembolic Disease, Post Thrombotic Syndrome
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic…
- Conditions
- Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life
- Trial name
- HOKUSAIpostVTE (NCT04007653)
- Testing
- Observation
- Where
- Netherlands
- Volunteers
- 1,200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Thromboembolic Pulmonary Hypertension
Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients
Balloon pulmonary angioplasty (BPA) emerged as a potential therapeutic option for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- NCT02964390
- Testing
- Balloon Pulmonary Angioplasty
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med
Hypertension, Pulmonary
THERAPY-HYBRID-BPA Trial
Riociguat could improve the exercise capacity and residual symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH) even after normalization of pulmonary arterial pressure by balloon pulmonary angioplasty…
- Trial name
- NCT04600492
- Testing
- Riociguat Oral Tablet
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- National Hospital Organization Okayama Medical Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Registry for Pulmonary Hypertension in China
1. To characterize the demographics and clinical course of the patient population diagnosed as having WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Death
- Trial name
- NCT01417338
- Where
- China
- Volunteers
- 3,079 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Chronic Thromboembolic Pulmonary Hypertension
Early Non-invasive Detection of CTEPH After Pulmonary Embolism
This is a prospective, international, multicenter outcome cohort study. This study starts at the moment patients visit the outpatient clinic 3 to 6 months after a diagnosis of acute PE as part of routine medical care.
- Trial name
- InShape2 (NCT02555137)
- Testing
- 'prediction score' and 'rule-out criteria'
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 424 people
- Sponsor
- Leiden University
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Pulmonary Hypertension, Primary, 4
Serum Bio-markers in Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart.
- Trial name
- NCT04472533
- Where
- United Kingdom
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Right Ventricular Failure, Chronic Thromboembolic Pulmonary Hypertension
Right Ventricular Resynchronization Therapy
The purpose of this study is to determine whether cardiac resynchronization therapy with the use of an implanted electronic pacemaker reduces morbidity associated with chronic thromboembolic pulmonary hypertension
- Conditions
- Right Ventricular Failure, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
- Trial name
- RVRT (NCT01163422)
- Testing
- Implantation of 3-chamber pacemaker
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Potential outcomes after PE occur on a spectrum: complete recovery, exercise intolerance from deconditioning/anxiety, dyspnea from concomitant cardiopulmonary conditions, dyspnea from residual pulmonary vascular occlusion…
- Trial name
- ValidSEARCH (NCT05568927)
- Testing
- SEARCH algorithm
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Chronic Thromboembolic Pulmonary Hypertension
Exercise Therapy After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
This study is being completed to determine the feasibility and acceptability of completing a home-based, structured, low-to-moderate intensity exercise training program in chronic thromboembolic pulmonary hypertension (CTEPH)…
- Trial name
- EXPECT-PH (NCT05693779)
- Testing
- Home exercise training
- Sponsor
- University of Michigan
Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
This study will help to provide more up to date prognostic data on the natural history of untreated proximal CTEPH which will be helpful in discussions regarding surgical versus medical treatment and by exploring the similarities…
- Trial name
- NCT02565030
- Where
- United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion
Venous Thromboembolism
Follow-up in Rivaroxaban Patients in Setting of Thromboembolism
In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes.
- Trial name
- FIRST (NCT02248610)
- Testing
- Non-interventional study
- Where
- 4 sites in United Kingdom
- Volunteers
- 1,343 people
- Sponsor
- King's College Hospital NHS Trust
Hypertension
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed treatment options exist.
- Trial name
- AMBER I (NCT01884675)
- Testing
- Ambrisentan 5 mg
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
Environmental factors may play a role in the genesis of pulmonary hypertension, especially in endothelial dysfunction. One widespread environmental factor associated with systemic endothelial dysfunction is cigarette smoke.
- Trial name
- DACH (NCT01484899)
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- University of Zurich
Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension
Long Term Outcomes of Venous Thromboembolism
This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC) rivaroxaban on the prevalence of…
- Conditions
- Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Venous Thrombosis
- Trial name
- LOVE (NCT02268630)
- Where
- 3 sites in Norway
- Volunteers
- 460 people
- Sponsor
- Ostfold Hospital Trust
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Covid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension
COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program
The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity…
- Conditions
- Covid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension, Myopathy, Restrictive Lung Disease
- Trial name
- COVISQAR (NCT04881214)
- Testing
- Pulmonary rehabilitation
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Geneva
Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Embolism
CTEPH in Patients With Prior Pulmonary Embolism and Risk Score Validation
CTEPH-SOLUTION aims to create a risk score for the early detection of Chronic Thrombo-Embolic Pulmonary Hypertension (CTEPH) among patients with previous pulmonary embolism.
- Trial name
- CTEPH-SOLUTION (NCT04681014)
- Where
- Italy
- Volunteers
- 1,218 people
- Sponsor
- iPHNET (italian Pulmonary Hypertension NETwork)